Price movement over the last 24 hours
Abeona Therapeutics Inc vs Build A Bear Workshop Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Build A Bear Workshop Inc trades at $30.09 (market cap $388.91M). The key difference: Abeona Therapeutics Inc and Build A Bear Workshop Inc are close in size by market cap, and Build A Bear Workshop Inc pays a 2.97% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BBW | |
|---|---|---|
Market Cap | $373.32M | $388.91M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $75.85 |
52-Week Low | $4.17 | $29.84 |
Enterprise Value | $228.22M | $488.35M |
Dividend Yield | — | 2.97% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Build-A-Bear Workshop (BBW) trades at $31.02, down 1.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics, including a P/E of 7.26 and a P/S of 0.76, alongside strong profitability with a net income margin of 10.48%. Recent developments include a CEO transition to Chris Hurt and the declaration of a $0.23 quarterly dividend payable in July 2026.
The long-term outlook is supported by a debt-free balance sheet, international expansion, and a 72.73% analyst buy rating with a $62.50 consensus price target, implying significant upside. Near-term risks include consumer spending pressures and revenue guidance reductions, but the fundamental setup remains attractive for recovery in the latter half of the year.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →